Literature DB >> 16570113

Frameless stereotactic subcaudate tractotomy for intractable obsessive-compulsive disorder.

P A Woerdeman1, P W A Willems, H J Noordmans, J W Berkelbach van der Sprenkel, P C van Rijen.   

Abstract

Obsessive-compulsive disorder (OCD) is a chronic, disabling disorder. Psychosurgery may be indicated for a subset of patients for whom no conventional treatment is satisfactory. This paper focuses on the stereotactic subcaudate tractotomy (SST). Thus far, these procedures have been carried out using frame-based stereotactic techniques. However, modern - highly accurate - frameless stereotactic procedures have successfully been introduced in neurosurgical practice. We developed a novel frameless stereotactic subcaudate tractotomy procedure with promising initial results in a patient suffering from intractable OCD. This is the first report on frameless SST. Future studies should examine whether other ablative stereotactic psychosurgery procedures can be done using frameless stereotactic methods.

Entities:  

Mesh:

Year:  2006        PMID: 16570113     DOI: 10.1007/s00701-006-0769-6

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  3 in total

Review 1.  MR imaging of psychosurgery: rostral atrophy following stereotacic subcaudate tractotomy.

Authors:  K A Cauley; W Waheed; M Salmela; C G Filippi
Journal:  Br J Radiol       Date:  2010-11       Impact factor: 3.039

Review 2.  Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD.

Authors:  Benjamin D Greenberg; Scott L Rauch; Suzanne N Haber
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

3.  Amygdala and Hypothalamus: Historical Overview With Focus on Aggression.

Authors:  Flavia Venetucci Gouveia; Clement Hamani; Erich Talamoni Fonoff; Helena Brentani; Eduardo Joaquim Lopes Alho; Rosa Magaly Campêlo Borba de Morais; Aline Luz de Souza; Sérgio Paulo Rigonatti; Raquel C R Martinez
Journal:  Neurosurgery       Date:  2019-07-01       Impact factor: 4.654

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.